Focused on High Value Cells

Solentim will present at Cell Series UK Virtual, the 9th Annual Cell Culture and Bioprocessing Conference

Solentim, the global leader for solutions to create, isolate and characterize the highest value cells for the development of new biological medicines, is pleased to present at Oxford Global’s 9th Annual Cell Culture and Bioprocessing Virtual Conference on the 6-7th October 2020.

Dr Ian Taylor, Chief Business Officer at Solentim, will be speaking on Day 1 (6th October 2020), at 2pm (BST) in the Stem Cell Therapy track. His talk, “Establishing New Standards  in Efficient Single Cell Cloning of hiPSCs” will look at how the development of a robust workflow for cloning iPSCs will have immediate potential to impact standards, consistency, and confidence of clonality between different laboratories in both academic and pharma research.

This year’s event offers 9 different tracks and covers 3 key themes:

  • Cell Culture & Bioprocessing
  • Regenerative Medicine & Advanced Therapy Development
  • Cell & Gene Therapy

The conference will connect international industry experts to share the ideas driving the cell culture and bioprocessing field forward, from establishing clonality in cell-line development, clinical developments in cell and gene therapy, case studies from industry leaders and challenges in manufacturing advanced therapies.

Dr Ian Taylor commented: “Cell line development and bioprocessing offer a huge amount of untapped potential; events like this give us the opportunity to come together and share advances to move the field onwards. I look forward to reconnecting with the industry and sharing our latest solutions for those working with stem cells to those in attendance.”

Register now for our upcoming webinar, “Establishing New Standards in Efficient Single Cell Cloning of hiPSCs”, taking place 22nd September, where we will discuss developing robust workflows for cloning hiPSCs for cell reprogramming and gene editing

Please get in touch to find out how Solentim can help you accelerate the development of your Master Cell Banks and ensure you are confidently prepared for regulatory review.

Translate »